A Samsung group arm is on track to win European regulatory approval for a near-replica version of the world’s top-selling drug, rheumatoid-arthritis treatment Humira.
WSJ.com: Asia Home, Wall Street Journal: Home Asia
Fri, 06/23/2017 - 11:25am
A Samsung group arm is on track to win European regulatory approval for a near-replica version of the world’s top-selling drug, rheumatoid-arthritis treatment Humira.